These are the two names that put this entire category on the map. If you've looked into appetite and weight medications at all, you've met semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). They're frequently treated as two versions of the same thing. They overlap a lot, but one meaningful design difference separates them, and it shows up in how they perform.
What semaglutide and tirzepatide have in common
Both reduce appetite, slow how quickly the stomach empties, and help regulate blood sugar, and both have produced substantial weight reduction in large clinical trials. Both are weekly injections, both are genuinely FDA-approved prescription medications (unlike most peptides discussed on this site), and both share a similar core side effect profile centered on the digestive system. They are far more alike than different, which is exactly why the comparison is worth making carefully. They've also drawn particular interest among women navigating the metabolic shifts of perimenopause and menopause, when weight can become harder to manage even without changes in habits.
How semaglutide works
Semaglutide is a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone your gut releases after eating that signals fullness, prompts insulin release, and slows digestion. Semaglutide mimics that single hormone by binding to and activating the GLP-1 receptor. It's the more targeted of the two, pulling one well-understood lever, and it has the longer real-world track record of widespread use behind it.
How tirzepatide works
Tirzepatide activates the same GLP-1 receptor but adds a second target: the GIP receptor. GIP, or glucose-dependent insulinotropic polypeptide, is a different gut hormone also involved in insulin response and metabolism. By engaging both pathways at once, tirzepatide is described as a dual agonist. The working theory is that activating the second receptor adds metabolic effects the single-receptor approach doesn't capture, which is the leading explanation for why tirzepatide has tended to produce larger average weight reduction in trials.
Key differences
The headline difference is the second receptor, and the most-watched consequence is weight results. Across the major trial programs, semaglutide produced average reductions in the mid-teens as a percentage of body weight, while tirzepatide reached roughly the low twenties at its higher doses, and a head-to-head trial designed to compare them directly found tirzepatide came out ahead on average. These are averages, not promises: individual responses vary widely, and plenty of people do very well on semaglutide. Treat the numbers as a general tendency rather than a guarantee for any one person.
Side effects are broadly similar in kind. Both most commonly cause nausea, and digestive effects like vomiting, diarrhea, or constipation, especially while the dose is being increased. Neither has a clearly gentler reputation across the board; tolerance is highly individual, and the standard approach with both is a slow dose increase to let the body adjust. If digestive side effects are your main worry, that concern applies to both rather than steering you toward one.
Access, cost, and availability often matter as much as the biology. Both have moved in and out of shortage, insurance coverage differs by the specific brand and indication, and out-of-pocket pricing is significant for both. In the research-compound gray market these are also sold unapproved, where quality and identity verification become the central concern. Whichever direction someone leans on the science, the practical decision usually comes down to what a prescriber recommends for their health profile and what they can actually obtain affordably.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP |
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
| Average weight result | Mid-teens percent | Roughly low twenties percent |
| Dosing | Weekly injection | Weekly injection |
| Main side effects | Digestive, dose-dependent | Digestive, dose-dependent |
| Approval status | FDA-approved | FDA-approved |
Bottom line
Tirzepatide tends to produce the larger average weight result, and for someone whose primary goal is maximum effect, the dual-receptor design has both a mechanistic rationale and head-to-head trial support behind it. It's the newer of the two but is well-studied and widely used at this point. If the science of the response is what's driving the decision, this is where the evidence currently leans.
Semaglutide remains an excellent and proven option with the longest real-world track record, and it suits people who respond well to it, have better access or coverage for it, or whose prescriber favors it for their situation. The gap between the two is real on average but not enormous, and a strong individual response to semaglutide can easily beat an average response to tirzepatide. The right answer is the one a qualified prescriber lands on with you, not a number from a trial. Cost, coverage, current availability, and how your body tolerates the dose increase often end up mattering as much as the average results.
Where to go from here
There's a third compound, retatrutide, that adds yet another receptor and is showing striking early results, covered alongside these two in the deeper GLP-1s explainer. If the GLP-1, GLP-2, GLP-3 naming has confused you, what those terms actually mean clears it up. To compare per-milligram pricing in the research market, the Peptide Price Lab tool tracks vendor costs in one place.